Annexin Pharmaceuticals AB (publ) (Q910) Stock Price & News

All values in SEK	Des. 2025	Mrt. 2026	Jun. 2026	Sep. 2026
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	8,00 m	7,92 m	8,48 m	6,89 m
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2,26 m	2,90 m	2,96 m	2,61 m
Operating expense	10,26 m	10,82 m	11,14 m	9,50 m
Total operating expenses	10,26 m	10,82 m	11,14 m	9,50 m
Operating income	-10,26 m	-10,82 m	-11,14 m	-9,50 m
Other non operating income	-	-	1,00 k	-
EBT including unusual items	-10,52 m	-10,52 m	-11,56 m	-9,49 m
EBT excluding unusual items	-10,52 m	-10,52 m	-11,56 m	-9,49 m
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-288,00 k	-
Net income	-10,52 m	-10,52 m	-11,56 m	-9,49 m
Net profit margin	-	-	-	-
Earnings per share	-	-	-	-
Interest and investment income	231,00 k	34,00 k	-	-
Interest expense	-	-	-	-
Net interest expenses	231,00 k	34,00 k	-	-
Depreciation and amortization charges	-	-	-	-
EBITDA	-10,21 m	-10,77 m	-11,10 m	-9,45 m
Gain or loss from assets sale	-	-	-	-

Finance